Grünenthal press release 2014

Welcome to Grünenthal's Press Overview

28 Nov 2014

Grünenthal Announces Termination of License Agreement with Actavis for the Development of Cebranopadol as of October 1, 2014

Grünenthal continues the clinical program as planned

Aachen, Germany, November 27, 2014. Grünenthal announced the termination of the license agreement with Actavis for the development and commercialization of Cebranopadol, a novel analgesic for the treatment of chronic pain.

More ...

18 Nov 2014

2014 Symposium on the Societal Impact of Pain (SIP): pain therapy and end-of-life care moves up to European agenda

European advocates call for EU action in the creation of a European Network for palliative care and pain therapy focusing on training of professionals and sharing of best practice.

Brussels, 18th November 2014. Better education on pain management and the need to foster European best practice sharing was discussed at the 5th Symposium on the Societal Impact of Pain (SIP),  an international multi stakeholder platform aimed at raising awareness for the impact that pain has on our societies, health and economic systems. Pain therapy and palliative care were listed as a priority by the Italian Presidency of the EU Council and, for the first time ever, all EU ministers of health discussed this topic at the recent informal Health Council meeting in September.

More ...

20 Oct 2014

Sascha Becker will join Grünenthal Group as new CFO

Aachen, Germany, October 20th 2014 Sascha Becker will be appointed to the Executive Board of the pharmaceutical company Grünenthal and take over the finance unit as Group Chief Financial Officer in the first quarter of 2015.

More ...

02 Oct 2014

"My pain feels like…" patient initiative gets the status of European best practice

Brussels, October 2th, 2014 – The “My pain feels like…” initiative is presented today at an EU conference hosted by the European Economic and Social Committee under the patronage of the Italian Presidency in Brussels. Active Citizenship Network organized the conference to put forward European good practices in chronic pain management, and “My pain feels like…” has been chosen one of these best practices across Europe.

More ...

23 Sep 2014

EFIC-Grünenthal Grant: Supporting up-and-coming researchers in the field of pain

Aachen/Brussels, September 23rd 2014. Young scientists from any European member country of the European Pain Federation EFIC® are invited to apply for the EFIC-Grünenthal Grant (E-G-G) 2014. This grant is one of the most prestigious and highly regarded pain research grants worldwide.

More ...

07 Jul 2014

AcelRx and Grünenthal Announce Submission of European Marketing Authorization Application for ZALVISOTM

MAA submission triggers $5 million milestone payment to AcelRx

Redwood City, California and Aachen, Germany – July 7, 2014 - AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) and Grünenthal Group announced today that Grünenthal has submitted a Marketing Authorization Application (MAA) to the European Medicines Authority for ZALVISO™ for the management of moderate to severe acute pain in adult patients in a medically supervised environment.

More ...

17 Jun 2014

Grünenthal presents new search fields at world’s largest biotechnology partnering conference

Aachen (Germany) / San Diego, CA (USA), June 17th, 2014. Grünenthal Group announces its new search fields for licensing and acquisition in R&D and for marketed assets at the 2014 BIO International Convention, the world’s largest partnering event for the biotechnology industry. The family owned, mid-sized research driven pharmaceutical company headquartered in Aachen, Germany, will be sharing with the biotech community its new approach to M&A and licensing.

More ...

07 May 2014

Grünenthal significantly strengthens its pain product portfolio in Europe

Aachen, May 7th 2014 – Grünenthal Group today announced the signing of an exclusive promotion and distribution agreement with MSD covering etoricoxib. This agreement covers Germany, UK, France, Belgium, Luxemburg, Ireland, and Austria. Etoricoxib is a patent-protected, selective COX-2 inhibitor, marketed under the brand name Arcoxia® in these markets.

More ...

08 Apr 2014

Grünenthal and Pain Alliance Europe urge EU and national authorities to improve chronic pain management

Multi-stakeholder views on chronic pain presented in the European Parliament/ Call to Action to fight chronic pain

Aachen/Brussels, April 8, 2014. On the occasion of an exhibition and cocktail reception hosted by Petru Luhan, Member of the European Parliament and winner of the MEP award for Health 2013, a multi-stakeholder platform of civic organizations, patient organizations, academia and industry, call on EU institutions and national authorities to recognize the societal and individual burden of chronic pain. During the exhibition in the European Parliament, the Pain Patient Pathway Recommendations will be presented to policy makers for the first time.

More ...